IMIPENEM: 1,879 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,879
Total FAERS Reports
604 (32.1%)
Deaths Reported
826
Hospitalizations
1,879
As Primary/Secondary Suspect
205
Life-Threatening
27
Disabilities
First Report: 18991231 · Latest Report: 20250527
What Are the Most Common IMIPENEM Side Effects?
#1 Most Reported
Drug ineffective
351 reports (18.7%)
#2 Most Reported
Off label use
202 reports (10.8%)
#3 Most Reported
Condition aggravated
138 reports (7.3%)
All IMIPENEM Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 351 | 18.7% | 156 | 176 |
| Off label use | 202 | 10.8% | 74 | 110 |
| Condition aggravated | 138 | 7.3% | 38 | 55 |
| Vomiting | 137 | 7.3% | 38 | 60 |
| Drug resistance | 117 | 6.2% | 27 | 44 |
| Nausea | 111 | 5.9% | 12 | 47 |
| Dyspnoea | 97 | 5.2% | 58 | 68 |
| Diarrhoea | 90 | 4.8% | 50 | 43 |
| Pyrexia | 90 | 4.8% | 30 | 61 |
| Product use in unapproved indication | 85 | 4.5% | 12 | 22 |
| Thrombocytopenia | 84 | 4.5% | 9 | 33 |
| Treatment failure | 82 | 4.4% | 48 | 38 |
| Multiple organ dysfunction syndrome | 80 | 4.3% | 63 | 35 |
| Electrocardiogram qt prolonged | 76 | 4.0% | 14 | 38 |
| Acute kidney injury | 71 | 3.8% | 23 | 42 |
| Death | 63 | 3.4% | 63 | 33 |
| Renal failure | 60 | 3.2% | 39 | 23 |
| Septic shock | 60 | 3.2% | 32 | 40 |
| Eosinophilia | 59 | 3.1% | 1 | 17 |
| Rash maculo-papular | 58 | 3.1% | 2 | 16 |
Who Reports IMIPENEM Side Effects? Age & Gender Data
Gender: 40.5% female, 59.5% male. Average age: 50.1 years. Most reports from: US. View detailed demographics →
Is IMIPENEM Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 3 | 2 | 1 |
| 2002 | 5 | 0 | 2 |
| 2008 | 1 | 0 | 0 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 1 | 1 |
| 2014 | 19 | 8 | 11 |
| 2015 | 29 | 6 | 17 |
| 2016 | 44 | 9 | 18 |
| 2017 | 96 | 45 | 48 |
| 2018 | 123 | 60 | 52 |
| 2019 | 84 | 31 | 55 |
| 2020 | 85 | 27 | 52 |
| 2021 | 103 | 11 | 41 |
| 2022 | 54 | 3 | 28 |
| 2023 | 23 | 0 | 6 |
| 2024 | 12 | 0 | 3 |
| 2025 | 9 | 0 | 2 |
What Is IMIPENEM Used For?
| Indication | Reports |
|---|---|
| Tuberculosis | 241 |
| Product used for unknown indication | 233 |
| Mycobacterium abscessus infection | 178 |
| Antibiotic therapy | 114 |
| Pulmonary tuberculosis | 92 |
| Nocardiosis | 85 |
| Infection | 64 |
| Pneumonia | 56 |
| Klebsiella infection | 37 |
| Sepsis | 37 |
IMIPENEM vs Alternatives: Which Is Safer?
IMIPENEM vs IMIPRAMINE
IMIPENEM vs IMIQUIMOD
IMIPENEM vs IMITREX
IMIPENEM vs IMMUNE GLOBULIN NOS
IMIPENEM vs IMPLANON
IMIPENEM vs INAVOLISIB
IMIPENEM vs INCIVEK
IMIPENEM vs INCIVO
IMIPENEM vs INCLISIRAN
IMIPENEM vs INCOBOTULINUMTOXINA
Official FDA Label for IMIPENEM
Official prescribing information from the FDA-approved drug label.